Subscribe

Articles

Final Results of the OPTIM-Imatinib Study in Patients with CP-CML
Hematologic Cancers
TON March 2016 Vol 9 No 2
Imatinib mesylate (IM) at 400 mg/day is the standard of care as first-line therapy in patients with newly diagnosed, chronic-phase chronic myeloid leukemia (CP-CML). Read More ›
Effect of Nilotinib Treatment Duration on Treatment-Free Remission in Patients with CP-CML
Hematologic Cancers
TON March 2016 Vol 9 No 2
In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission with nilotinib in patients with chronic-phase chronic myeloid leukemia (CP-CML). Read More ›
Preparation of Nurses for Cancer Survivorship Care
By Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
A collaborative program between Memorial Sloan Kettering Cancer Center in New York, NY, and the City of Hope in Duarte, CA, has helped educate nurses about survivorship care and facilitate their development at their own institutions. Read More ›
Providing Oncology Care Across the Cancer Care Continuum
By Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
A study evaluating a new model for education of primary care nurse practitioners (NPs) in oncology practice has shown effective delivery of essential basic care competencies. Read More ›
Bridging the Gap Between Pediatric and Adult Care
By Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
To decrease barriers to transition for childhood cancer survivors, Children’s Mercy Hospital and the University of Kansas Cancer Center (KUCC), Mercy Hospital, Kansas City, MO, have collaborated to develop the Survivorship Transition Clinic (STC). Read More ›
PD-1 Inhibitors May Be Effective in Patients with Gastrointestinal Cancers
By Christine Erickson
Gastrointestinal Cancers
TON March 2016 Vol 9 No 2
Although immunotherapy drugs targeting programmed cell death-1 (PD-1) have proved to be effective in patients with melanoma and lung cancer, new data from 2 recent studies suggest that these drugs may also be effective in patients with certain gastrointestinal cancers. Read More ›
Noteworthy Numbers: Colorectal Cancer
Noteworthy Numbers: Colorectal Cancer
Noteworthy Numbers
TON March 2016 Vol 9 No 2
The first National Colorectal Cancer Awareness Month was designated in March 2000. Since then, organizations throughout the country have dedicated March to increasing awareness of this disease and encouraging Americans to be screened. Here are some statistics and current information about colorectal cancer (CRC). Read More ›
Crizotinib Receives Expanded FDA-Approval to Treat Patients with Rare NSCLC
FDA Updates, In the News
Web Exclusives
Crizotinib (Xalkori) has been approved for expanded use in patients with metastatic non−small-cell lung cancer (NSCLC) whose tumors have an ROS1 gene alteration, according to an announcement by the US Food and Drug Administration (FDA). The first and only approved treatment for this patient population, crizotinib blocks ROS1 protein activity in tumors, possibly preventing NSCLC from spreading. Read More ›
FDA Expands Use of Xalkori to Treat Rare Form of Advanced Non-Small Cell Lung Cancer
FDA Updates, In the News
Web Exclusives
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Read More ›
Oral Therapies for Multiple Myeloma Continuum
Oral Therapies for Multiple Myeloma Continuum
Supplements
From 2004 to 2013, 22 new oral anticancer medications were introduced in the United States, which is almost the same number (27) of oral anticancer medications that were introduced in the previous 50 years combined. Of the US Food and Drug Administration (FDA)-approved myeloma novel therapies, 5 are orally administered. With the FDA approval of ixazomib (Ninlaro; a first-in-class oral proteasome inhibitor) in November 2015, an all-oral treatment combination for patients with myeloma is now a reality with the combination of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron) Read More ›

Page 203 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.